Patents by Inventor Carsten Olbrich
Carsten Olbrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11052128Abstract: The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions.Type: GrantFiled: November 5, 2013Date of Patent: July 6, 2021Assignee: AMGEN INC.Inventors: Carsten Olbrich, Thomas Bunte, Jonas Winter, Jörg Peters, Thomas Trill
-
Publication number: 20190367636Abstract: The present invention refers to novel liquid pharmaceutical formulations comprising human antibody against coagulation factor FXIa as active ingredient. The invention also refers to lyophilizates of the specified liquid formulation and also to the use thereof in the therapy and prophylaxis of thrombotic or thromboembolic disorder.Type: ApplicationFiled: January 16, 2018Publication date: December 5, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Carsten OLBRICH, Thomas TRILL, Marieke VEURINK
-
Patent number: 10407489Abstract: A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of: a) freezing droplets of a solution comprising factor VIII to form pellets; b) freeze-drying the pellets; wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.Type: GrantFiled: November 4, 2016Date of Patent: September 10, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Carsten Olbrich, Matthias Plitzko, Bernhard Luy, Stefan Christian Schneid
-
Publication number: 20190240345Abstract: The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate MF-T-SPDB-DM4. The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization. The lyophilized powder can be reconstituted with water to create a reconstituted solution which is again suitable for therapeutic applications. It is a further object to provide a stable reconstituted protein formulation which is suitable for therapeutic administrations.Type: ApplicationFiled: February 12, 2019Publication date: August 8, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Carsten OLBRICH, Thomas TRILL
-
Publication number: 20180327478Abstract: A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of: a) freezing droplets of a solution comprising factor VIII to form pellets; b) freeze-drying the pellets; wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Carsten OLBRICH, Matthias PLITZKO, Bernhard LUY, Stefan Christian SCHNEID
-
Publication number: 20160250349Abstract: The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate MF-T-SPDB-DM4. The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization. The lyophilized powder can be reconstituted with water to create a reconstituted solution which is again suitable for therapeutic applications. It is a further object to provide a stable reconstituted protein formulation which is suitable for therapeutic administrations.Type: ApplicationFiled: October 21, 2014Publication date: September 1, 2016Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Carsten OLBRICH, Thomas TRILL
-
Patent number: 9308284Abstract: The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.Type: GrantFiled: June 21, 2012Date of Patent: April 12, 2016Assignee: PIRAMAL IMAGING SAInventors: Carsten Olbrich, Michael Krause, Andreas Burkhard, Annett Richter, Rainer Braun
-
Publication number: 20150335706Abstract: The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions.Type: ApplicationFiled: November 5, 2013Publication date: November 26, 2015Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Carsten OLBRICH, Thomas BUNTE, Jonas WINTER, Jörg PETERS, Thomas TRILL
-
Publication number: 20140241986Abstract: The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.Type: ApplicationFiled: June 21, 2012Publication date: August 28, 2014Applicant: PIRAMAL IMAGING SAInventors: Carsten Olbrich, Michael Krause, Andreas Burkhard, Annett Richter, Rainer Braun
-
Publication number: 20120328521Abstract: The invention is directed to formulations of lipophilic Amyloid ?eta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously wherein the lipophilic Amyloid ?eta ligand stilbene based derivative is a 19F or 18F-labeled radiopharmaceutical thereof. Further, the invention is directed to a method for sterile filtration of said suitable formulation.Type: ApplicationFiled: December 22, 2010Publication date: December 27, 2012Applicant: PIRAMAL IMAGING SAInventors: Carsten Olbrich, Michael Krause, Andreas Burkhard
-
Publication number: 20120237532Abstract: A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs.Type: ApplicationFiled: March 8, 2012Publication date: September 20, 2012Applicant: Icon Genetics GmbHInventors: Carsten Olbrich, Michael Krause, Thomas Trill
-
Patent number: 6770299Abstract: The invention relates to particulate active ingredient vehicles which are in the solid aggregate state at room temperature (20° C.) and consist of a pure lipid-drug conjugate (LDC) or a mixture of several LDCs as particle matrix, the bond in the LDC being effected by covalent bonding, electrostatic interactions, dipole moments, dispersion forces, ion interactions, hydrogen bridges and/or hydrophobic interactions.Type: GrantFiled: January 14, 2002Date of Patent: August 3, 2004Assignee: PharmaSol GmbHInventors: Rainer H. Müller, Carsten Olbrich